Bionano Genomics Inc (BNGO)

2.220
-0.030(-1.33%)
After Hours
2.250
+0.030(+1.351%)
- Real-time Data
  • Volume:
    1,435,000
  • Day's Range:
    2.210 - 2.265
  • 52 wk Range:
    1.160 - 4.350

BNGO Overview

Prev. Close
2.25
Day's Range
2.21-2.265
Revenue
25.89M
Open
2.23
52 wk Range
1.16-4.35
EPS
-0.409
Volume
1,435,000
Market Cap
659.17M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
6,456,394
P/E Ratio
-
Beta
2.26
1-Year Change
-45.72%
Shares Outstanding
296,924,500
Next Earnings Date
16 Mar 2023
What is your sentiment on Bionano Genomics?
or
Market is currently closed. Voting is open during market hours.

Bionano Genomics Inc News

Bionano Genomics Inc Analysis

Bionano Genomics Inc Company Profile

Bionano Genomics Inc Company Profile

Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • can anyone tell me why a sudden share price movement? not that am complaining.
    0
    • pump and dump traders are back
      2
    • Rumours / inside knowledge of potential buy-out
      0
  • Nice!
    0
  • Lets go bulls
    1
    • I want it to explode… explode I Say!
      1
      • farewell my lady
        0
        • Back to $5 by May
          2
          • 😂😂😂
            0
          • Dreaming is foc lol
            0
        • Good news and adding a few more. GLTA
          1
          • Biggest and costly mistake of believing the hype.
            1
            • that's the bear market for you. I do think growth stocks will bounce back later this year as lots of them are extremely undervalued i.e nndm when compare ts its market cap vs cash on hand. big question is when?
              1
          • dead
            0
            • Added more today. Glta
              2
              • I like your Optimism. I hope it starts to rise consistently after their Symposium, as its painful AF ATM.
                2